GRC 17536

Drug Profile

GRC 17536

Alternative Names: GRC 17536 potassium powder for inhalation - Glenmark Pharmaceuticals; GRC-17536

Latest Information Update: 18 Sep 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Glenmark Pharmaceuticals Ltd
  • Class Analgesics; Anti-inflammatories; Antiasthmatics; Antitussives
  • Mechanism of Action TRPA1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cough; Neuropathic pain
  • Phase I/II Allergic asthma

Most Recent Events

  • 18 Sep 2017 GRC 17536 is still in clinical trials for Neuropathic pain and Respiratory disorders (Glenmark pipeline, September 2017)
  • 22 Aug 2016 Glenmark Pharmaceuticals files an IND application with the FDA in USA for conducting a phase IIb trial in Neuropathic pain (Glenmark Pharmaceuticals website) before August 2016
  • 16 Aug 2016 Glenmark Pharmaceuticals completes a phase I drug-drug interaction trial in Healthy volunteers in India (PO) before August 2016 (CTRI2015-01-005417)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top